Older Adult Perspectives on Statin Continuation and Discontinuation in Primary Cardiovascular Disease Prevention: A Mixed-Methods Study

References

• O’Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using the health improvement network primary care data. Clin Epidemiol. 2016;8:123–132. doi:10.2147/CLEP.S104258
   PubMed Web of Science ®Google Scholar
• Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. NCHS Data Brief. 2014;177:1–8.
   Google Scholar
• Canadian Institute for Health Information. Drug use among seniors in Canada; 2016. Available from: https://www.cihi.ca/sites/default/files/document/drug-use-among-seniors-2016-en-web.pdf. Accessed May 15, 2022.
   Google Scholar
• Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37–45. doi:10.1016/j.jacc.2007.06.063
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. for the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e143. doi:10.1161/CIR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Armitage J, Baigent C, Barnes E; Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–415. doi:10.1016/S0140-6736(18)31942-1
   PubMed Web of Science ®Google Scholar
• Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:l5674. doi:10.1136/bmj.l5674
   PubMedGoogle Scholar
• Chokshi NP, Messerli FH, Sutin D, Supariwala AA, Shah NR. Appropriateness of statins in patients aged >/=80 years and comparison to other age groups. Am J Cardiol. 2012;110(10):1477–1481. doi:10.1016/j.amjcard.2012.06.058
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197. doi:10.1136/bmj.c2197
   PubMed Web of Science ®Google Scholar
• Holmes HM, Todd A. The role of patient preferences in deprescribing. Clin Geriatr Med. 2017;33(2):165–175. doi:10.1016/j.cger.2017.01.004
   PubMed Web of Science ®Google Scholar
• Linsky A, Meterko M, Bokhour BG, Stolzmann K, Simon SR. Deprescribing in the context of multiple providers: understanding patient preferences. Am J Manag Care. 2019;25(4):192–198. doi:10.7326/0003-4819-140-10-200405180-00009
   PubMed Web of Science ®Google Scholar
• van der Ploeg MA, Floriani C, Achterberg WP, et al. Recommendations for (Discontinuation of) Statin treatment in older adults: review of guidelines. J Am Geriatr Soc. 2020;68(2):417–425. doi:10.1111/jgs.16219
   PubMed Web of Science ®Google Scholar
• Pickering AN, Hamm ME, Dawdani A, et al. Older patient and caregiver perspectives on medication value and deprescribing: a qualitative study. J Am Geriatr Soc. 2020;68(4):746–753. doi:10.1111/jgs.16370
   PubMed Web of Science ®Google Scholar
• Qi K, Reeve E, Hilmer SN, Pearson S-A, Matthews S, Gnjidic D. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37(5):949–957. doi:10.1007/s11096-015-0147-7
   PubMed Web of Science ®Google Scholar
• Luymes CH, Boelhouwer NJ, Poortvliet RK, de Ruijter W, Reis R, Numans ME. Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients. Patient Prefer Adherence. 2017;11:975–984. doi:10.2147/PPA.S131625
   PubMed Web of Science ®Google Scholar
• Tjia J, Kutner JS, Ritchie CS, et al. Perceptions of statin discontinuation among patients with life-limiting illness. J Palliat Med. 2017;20(10):1098–1103. doi:10.1089/jpm.2016.0489
   PubMed Web of Science ®Google Scholar
• Pluye P, Hong QN. Combining the power of stories and the power of numbers: mixed methods research and mixed studies reviews. Annu Rev Public Health. 2014;35(1):29–45. doi:10.1146/annurev-publhealth-032013-182440
   PubMed Web of Science ®Google Scholar
• Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443–452. doi:10.1007/s41999-021-00479-3
   PubMed Web of Science ®Google Scholar
• Setia MS. Methodology series module 5: sampling strategies. Indian J Dermatol. 2016;61(5):505–509. doi:10.4103/0019-5154.190118
   PubMed Web of Science ®Google Scholar
• Fetters MD. Developing a joint display. In: Fargotstein LJA, Todorovic-Arndt L, editors. The Mixed Methods Research Workbook: Activities for Designing, Implementing, and Publishing Projects. California (USA): SAGE Publications, Inc.; 2019:193–210.
   Google Scholar
• Sandelowski M. Sample size in qualitative research. Res Nurs Health. 1995;18(2):179–183. doi:10.1002/nur.4770180211
   PubMed Web of Science ®Google Scholar
• Rach C, Lukas J, Müller R, Sendler M, Simon P, Salloch S. Involving patient groups in drug research: a systematic review of reasons. Patient Prefer Adherence. 2020;14:587–597. doi:10.2147/PPA.S232499
   PubMed Web of Science ®Google Scholar
• Reeve E, Low LF, Shakib S, Hilmer SN. Development and validation of the revised patients’ Attitudes Towards Deprescribing (rPATD) questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33(12):913–928. doi:10.1007/s40266-016-0410-1
   PubMed Web of Science ®Google Scholar
• Brunner L, Rodondi N, Aubert CE. Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review. BMJ Open. 2022;12(12):e061686. doi:10.1136/bmjopen-2022-061686
   PubMed Web of Science ®Google Scholar
• AM O’Connor. The things that are important to me when making a decision about tamoxifen; 1999. Available from: https://decisionaid.ohri.ca/docs/develop/Tools/Values_tamoxifen.pdf. Accessed May15, 2022.
   Google Scholar
• Burnard P, Gill P, Stewart K, Treasure E, Chadwick B. Analysing and presenting qualitative data. Br Dent J. 2008;204(8):429–432. doi:10.1038/sj.bdj.2008.292
   PubMed Web of Science ®Google Scholar
• Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398–405. doi:10.1111/nhs.12048
   PubMed Web of Science ®Google Scholar
• Luymes CH, van der Kleij RM, Poortvliet RK, de Ruijter W, Reis R, Numans ME. Deprescribing potentially inappropriate preventive cardiovascular medication: barriers and enablers for patients and general practitioners. Ann Pharmacother. 2016;50(6):446–454. doi:10.1177/1060028016637181
   PubMed Web of Science ®Google Scholar
• Jansen J, McKinn S, Bonner C, Muscat DM, Doust J, McCaffery K. Shared decision-making about cardiovascular disease medication in older people: a qualitative study of patient experiences in general practice. BMJ Open. 2019;9(3):e026342. doi:10.1136/bmjopen-2018-026342
   PubMed Web of Science ®Google Scholar
• van Bussel E, Reurich L, Pols J, Richard E, Moll van Charante E, Ligthart S. Hypertension management: experiences, wishes and concerns among older people-A qualitative study. BMJ Open. 2019;9(8):e030742. doi:10.1136/bmjopen-2019-030742
   PubMed Web of Science ®Google Scholar
• Crutzen S, Baas G, Abou J, et al. Barriers and enablers of older patients to deprescribing of cardiometabolic medication: a focus group study. Front Pharmacol. 2020;11:1268. doi:10.3389/fphar.2020.01268
   PubMed Web of Science ®Google Scholar
• Benson J, Britten N. What effects do patients feel from their antihypertensive tablets and how do they react to them? Qualitative analysis of interviews with patients. Fam Pract. 2006;23(1):80–87. doi:10.1093/fampra/cmi081
   PubMed Web of Science ®Google Scholar
• Goyal P, Requijo T, Siceloff B, et al. Patient-reported barriers and facilitators to deprescribing cardiovascular medications. Drugs Aging. 2020;37(2):125–135. doi:10.1007/s40266-019-00729-x
   PubMed Web of Science ®Google Scholar
• van Middelaar T, Ivens SD, van Peet PG, et al. Prescribing and deprescribing antihypertensive medication in older people by Dutch general practitioners: a qualitative study. BMJ Open. 2018;8(4):e020871. doi:10.1136/bmjopen-2017-020871
   PubMed Web of Science ®Google Scholar
• Rozsnyai Z, Jungo KT, Reeve E, et al. What do older adults with multimorbidity and polypharmacy think about deprescribing? The LESS study - A primary care-based survey. BMC Geriatr. 2020;20(1):435. doi:10.1186/s12877-020-01843-x
   PubMed Web of Science ®Google Scholar
• Weir K, Nickel B, Naganathan V, et al. Decision-making preferences and deprescribing: perspectives of older adults and companions about their medicines. J Gerontol B Psychol Sci so Sci. 2018;73(7):e98–e107. doi:10.1093/geronb/gbx138
   PubMed Web of Science ®Google Scholar